Calystegines through the maintenance of the AKT/PI3K/mTOR pathway mitigate ER stress and therefore ensure ASCs survival and proper metabolic activity in a hyperglycaemic milieu, making calystegines a promising alternative for the effective management of metabolic conditions associated with hyperglycemia including diabetes mellitus, obesity and metabolic syndrome. Here, AKT1 is linked to obesity due to melanocortin 4 receptor deficiency.